Medicine and Health
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
T. Munir, D. Cairns, et al.
This groundbreaking phase 3 trial reveals that MRD-directed ibrutinib-venetoclax significantly enhances progression-free and overall survival rates in untreated CLL patients. The study showcases a remarkable 58% of patients achieving undetectable MRD and stopping therapy after three years. Conducted by a team of leading researchers, including T. Munir and D.A. Cairns, this research highlights both the efficacy and cardiac risks associated with the novel treatment.
Related Publications
Explore these studies to deepen your understanding of the subject.
